Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling
- PMID: 32135457
- DOI: 10.1016/j.phymed.2020.153191
Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling
Abstract
Background: Atractylenolide I (ATL-1) is a natural herbal compound used in traditional Chinese medicine that has exhibited anti-cancer properties. The anti-tumorigenic activity of ATL-1 against colorectal cancer (CRC) and the underlying signaling pathways involved in its mechanisms are examined here.
Hypothesis: ATL-1 exerts therapeutic effect against CRC by disrupting glucose metabolism and cancer stem cell maintenance via AKT/mTOR pathway regulation.
Study design: In vitro studies were performed in COLO205 and HCT116 CRC cell lines and in vivo studies were conducted in a mouse xenograft model of CRC tumor.
Methods: CRC cells were treated with ATL-1 at various concentrations, with or without inhibitors of AKT or mTOR. Cell proliferation, apoptosis, invasion, stemness maintenance, glucose metabolism, and AKT/mTOR signaling were evaluated. CRC tumor-xenografted mice were treated with an AKT inhibitor and/or ATL-1, and glucose metabolism and stemness maintenance were examined in tumor tissues.
Results: ATL-1 significantly inhibited the invasion of CRC cells by inducing their apoptosis, possibly via the excessive production of reactive oxygen species. Glucose metabolism (Warburg effect) was also altered and stem-like traits were suppressed by ATL-1. In addition, ATL-1 effectively acted as an inhibitor or AKT/mTOR by downregulating the phosphorylation of proteins related to the AKT/mTOR pathway. In vivo studies showed that tumor weight and volume were reduced by ATL-1 and that aerobic glycolysis, stemness maintenance, and AKT/mTOR activation were impaired by ATL-1 in colorectal tumors.
Conclusions: ATL-1 acts as an effective agent to suppress colorectal tumor progression, mainly by inhibiting CRC cell proliferation through altering apoptosis, glucose metabolism, and stem-like behavior. These processes were mediated by the AKT/mTOR signaling pathway both in vitro and in vivo. ATL-1 may be a potential agent to be used in molecular-targeted strategies for cancer treatment.
Keywords: AKT/mTOR signaling; Apoptosis; Cell behavior; Gastrointestinal; Glucose metabolism; Traditional Chinese medicine.
Copyright © 2020 Elsevier GmbH. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no competing interests.
Similar articles
-
Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway.Pharm Biol. 2019 Dec;57(1):412-423. doi: 10.1080/13880209.2019.1626447. Pharm Biol. 2019. PMID: 31230505 Free PMC article.
-
Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.Biochem Pharmacol. 2020 Jan;171:113680. doi: 10.1016/j.bcp.2019.113680. Epub 2019 Oct 25. Biochem Pharmacol. 2020. PMID: 31669234
-
Atractylenolide I regulates colorectal cancer cells' biological processes and glycolysis via KRT7.Pak J Pharm Sci. 2024 Nov-Dec;37(6):1213-1222. Pak J Pharm Sci. 2024. PMID: 39799436
-
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.Int J Mol Sci. 2024 Mar 9;25(6):3178. doi: 10.3390/ijms25063178. Int J Mol Sci. 2024. PMID: 38542151 Free PMC article. Review.
-
PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.Curr Drug Targets. 2019;20(12):1217-1226. doi: 10.2174/1389450120666190618123846. Curr Drug Targets. 2019. PMID: 31215384 Review.
Cited by
-
Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance.Transl Oncol. 2024 Dec;50:102156. doi: 10.1016/j.tranon.2024.102156. Epub 2024 Oct 13. Transl Oncol. 2024. PMID: 39405607 Free PMC article. Review.
-
Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways.Cancer Drug Resist. 2025 Mar 24;8:13. doi: 10.20517/cdr.2024.178. eCollection 2025. Cancer Drug Resist. 2025. PMID: 40201307 Free PMC article. Review.
-
Natural products target programmed cell death signaling mechanisms to treat colorectal cancer.Front Pharmacol. 2025 Apr 24;16:1565332. doi: 10.3389/fphar.2025.1565332. eCollection 2025. Front Pharmacol. 2025. PMID: 40342991 Free PMC article. Review.
-
Atractylenolide I inhibits the growth, proliferation and migration of B16 melanoma cells via the PI3K/AKT/mTOR pathway.Oncol Lett. 2025 May 30;30(2):372. doi: 10.3892/ol.2025.15118. eCollection 2025 Aug. Oncol Lett. 2025. PMID: 40503042 Free PMC article.
-
Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70.Ther Adv Med Oncol. 2020 Sep 10;12:1758835920953728. doi: 10.1177/1758835920953728. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32973929 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous